Practical aspects of metastatic castration-resistant prostate cancer management: Patient case studies

BJU International

Volumn 109, Issue SUPPL. 2, 2012, Pages 14-19

  Bahl, Amit ^a   Bellmunt, Joaquim ^b   Oudard, Stéphane ^c  

^a BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^b HOSPITAL DEL MAR   (Spain)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

androgen deprivation therapy; cabazitaxel; chemotherapy; CRPC; multidisciplinary team; patient centred approach; prognostic factors; radiation therapy

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; CABAZITAXEL; DIETHYLSTILBESTROL; DOCETAXEL; DOCUSATE SODIUM; GONADORELIN AGONIST; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; ZOLEDRONIC ACID;

AGED; ANDROGEN DEPRIVATION THERAPY; ANEMIA; BONE METASTASIS; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; CONSTIPATION; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG TOLERABILITY; DRUG WITHDRAWAL; EUROPE; FATIGUE; GLEASON SCORE; HUMAN; HUMAN TISSUE; HYDRONEPHROSIS; LIVER METASTASIS; LYMPH NODE METASTASIS; LYMPHADENOPATHY; MALE; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NOCTURIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT CARE; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATECTOMY; RADIATION DOSE; RECOMMENDED DRUG DOSE; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT RESPONSE; UNITED STATES; URETER OBSTRUCTION; VISCERAL METASTASIS;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CONGRESSES AS TOPIC; DRUG RESISTANCE, NEOPLASM; HUMANS; LIVER NEOPLASMS; MALE; PALLIATIVE CARE; PATIENT-CENTERED CARE; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; TAXOIDS;

EID: 84856208001     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10872.x     Document Type: Conference Paper

References (18)

1. Attard G, Cooper CS, de Bono JS,. Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell 2009; 16: 458-62
2. Mottet N, Bellmunt J, Bolla M, et al,. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011; 59: 572-83
3. US Food and Drug Administration. Cabazitaxel. Available from:. 2011. Accessed November 2011
4. European Medicines Agency. Jevtana (cabazitaxel). Available from:. 2011. Accessed November 2011
5. de Bono JS, Oudard S, Ozguroglu M, et al,. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-54
6. Eymard JC, Oudard S, Gravis G, et al,. Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study. BJU Int 2010; 106: 974-8
7. Loriot Y, Massard C, Gross-Goupil M, et al,. The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. Eur J Cancer 2010; 46: 1770-2
8. Semeniuk RC, Venner PM, North S,. Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer. Urology 2006; 68: 565-9 (Pubitemid 44436503)
9. Oudard S, Banu E, Scotte F, et al,. Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients. Ann Oncol 2007; 18: 1828-33 (Pubitemid 350111569)
10. Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M,. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 2007; 13: 6396-403 (Pubitemid 350075029)
11. Bidart JM, Thuillier F, Augereau C, et al,. Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin Chem 1999; 45: 1695-707 (Pubitemid 29477325)
12. Armstrong AJ, Tannock IF, de Wit R, George DJ, Eisenberger M, Halabi S,. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer 2010; 46: 517-25
13. Armstrong AJ, Garrett-Mayer E, de Wit R, Tannock I, Eisenberger M,. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 2010; 16: 203-11
14. Tombal B, Oudard S, Ozguroglu M, et al,. Clinical benefit of cabazitaxel plus prednisone in the TROPIC trial in men with metastatic castration resistant prostate cancer (mCRPC) who progressed after docetaxel-based treatment. European Association of Urology Congress, Vienna, 2011. Abstract 1090
15. Smith TJ, Khatcheressian J, Lyman GH, et al,. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24: 3187-205 (Pubitemid 46638957)
16. Ozguroglu M, Oudard S, Sartor AO, et al,. Effect of G-CSF prophylaxis on the occurrence of neutropenia in men receiving cabazitaxel plus prednisone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in the TROPIC study. J Clin Oncol 2011; 29: suppl. 7, Abstract 144
17. Sanofi-Aventis. Jevtana US prescribing information. 2011
18. Heidenreich A, Bellmunt J, Bolla M, et al,. EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011; 59: 61-71